# Egle Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/egle-therapeutics

- Industry: Biotechnology
- Headquarters: Suresnes, France
- Website: www.egle-tx.com
- Total disclosed funding: $17M
- Latest round: Series A (Oct 12, 2021)
- Investors on record: 6

## About

Egle Therapeutics SAS, based in Paris, France, is a biotechnology company focused on developing innovative therapies that engage regulatory T cells to treat cancer and autoimmune diseases. Founded in 2020 in Paris, France, Egle Therapeutics specializes in therapies targeting regulatory T cells (Tregs). Egle Therapeutics specializes in the development of innovative therapies targeting regulatory T cells (Tregs) for cancer and autoimmune diseases. Their lead products include EGL-001, currently in clinical trials for oncology (NCT06622486), and EGL-003, which has completed IND-enabling studies and plans to enter Phase I trials in 2025. The company employs a proprietary discovery platform that utilizes multi-omics analyses and bioinformatics to identify therapeutic Treg targets, focusing on markets in North America and Europe. Their revenue model encompasses B2B transactions with biopharmaceutical companies and research organizations, leading to funding for clinical development in exchange for rights to develop therapies. This structure also includes milestone payments and royalties on future product sales as the company advances its lead products. In March 2026, Egle Therapeutics raised EUR 8 million in grant funding from Horizon Europe.

## Funding rounds

- Series A, Oct 12, 2021, $17M — EQT Life Sciences, Takeda Ventures, Bpifrance Investissement, Fund+, JDRF T1D Fund, Bioqube Ventures

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A
- Fund+ (https://capitalatlas.ai/funds/fund) — Series A
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series A
- Bioqube Ventures (https://capitalatlas.ai/funds/bioqube-ventures) — Series A